NZ334941A - Methods for treating infections using proteins which induce an immune response in one animal species but not in another - Google Patents
Methods for treating infections using proteins which induce an immune response in one animal species but not in anotherInfo
- Publication number
- NZ334941A NZ334941A NZ334941A NZ33494197A NZ334941A NZ 334941 A NZ334941 A NZ 334941A NZ 334941 A NZ334941 A NZ 334941A NZ 33494197 A NZ33494197 A NZ 33494197A NZ 334941 A NZ334941 A NZ 334941A
- Authority
- NZ
- New Zealand
- Prior art keywords
- proteins
- antisera
- antibodies
- hiv
- human
- Prior art date
Links
- 208000015181 infectious disease Diseases 0.000 title abstract 4
- 230000028993 immune response Effects 0.000 title abstract 3
- 102000004169 proteins and genes Human genes 0.000 title abstract 3
- 108090000623 proteins and genes Proteins 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 108010048209 Human Immunodeficiency Virus Proteins Proteins 0.000 abstract 3
- 241000124008 Mammalia Species 0.000 abstract 2
- 108090000288 Glycoproteins Proteins 0.000 abstract 1
- 102000003886 Glycoproteins Human genes 0.000 abstract 1
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 abstract 1
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 abstract 1
- 102100034343 Integrase Human genes 0.000 abstract 1
- 108091005804 Peptidases Proteins 0.000 abstract 1
- 239000004365 Protease Substances 0.000 abstract 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 abstract 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 abstract 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 abstract 1
- 101800001690 Transmembrane protein gp41 Proteins 0.000 abstract 1
- 238000002967 competitive immunoassay Methods 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 230000001900 immune effect Effects 0.000 abstract 1
- 239000006166 lysate Substances 0.000 abstract 1
- 244000052769 pathogen Species 0.000 abstract 1
- 230000001717 pathogenic effect Effects 0.000 abstract 1
- 239000002243 precursor Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000004043 responsiveness Effects 0.000 abstract 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
- C07K16/1054—Lentiviridae, e.g. HIV, FIV, SIV gag-pol, e.g. p17, p24
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
- C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/5555—Muramyl dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Hematology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Wood Science & Technology (AREA)
- Communicable Diseases (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ507680A NZ507680A (en) | 1996-10-10 | 1997-10-10 | Immunomodulators and carriers for immunogenic peptides comprising multiple repeats of muramyl dipeptide |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2819496P | 1996-10-10 | 1996-10-10 | |
| PCT/US1997/018257 WO1998015658A1 (en) | 1996-10-10 | 1997-10-10 | Compositions and methods for treating viral infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ334941A true NZ334941A (en) | 2000-11-24 |
Family
ID=21842081
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ334941A NZ334941A (en) | 1996-10-10 | 1997-10-10 | Methods for treating infections using proteins which induce an immune response in one animal species but not in another |
Country Status (11)
| Country | Link |
|---|---|
| US (6) | US6043347A (enExample) |
| EP (1) | EP0939835A4 (enExample) |
| JP (2) | JP2001502315A (enExample) |
| KR (2) | KR100667121B1 (enExample) |
| CN (1) | CN1327896C (enExample) |
| AU (1) | AU732809B2 (enExample) |
| BR (1) | BR9712289A (enExample) |
| CA (1) | CA2268372C (enExample) |
| MX (1) | MXPA02010374A (enExample) |
| NZ (1) | NZ334941A (enExample) |
| WO (1) | WO1998015658A1 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2268372C (en) * | 1996-10-10 | 2012-11-27 | Probe International | Compositions and methods for treating viral infections |
| US7157091B1 (en) * | 1999-06-18 | 2007-01-02 | Ludwig Institute For Cancer Research | MAGE-A1 peptides presented by HLA class II molecules |
| US6599441B1 (en) * | 2000-07-18 | 2003-07-29 | Emerald Biostructures, Inc. | Crystallization solutions |
| CN1339319A (zh) * | 2000-08-18 | 2002-03-13 | 清华大学 | 一种治疗艾滋病的药物及其制备方法 |
| US6987184B2 (en) * | 2001-02-15 | 2006-01-17 | Signal Pharmaceuticals, Llc | Isothiazoloanthrones, isoxazoloanthrones, isoindolanthrones and derivatives thereof as JNK inhibitors and compositions and methods related |
| JP2007524609A (ja) * | 2003-04-10 | 2007-08-30 | トランスフォーム・ファーマシューティカルズ・インコーポレイテッド | コンフォメーションに関する変種のプロファイリング、抗体組成物 |
| US7206991B2 (en) * | 2003-10-15 | 2007-04-17 | Lsi Logic Corporation | Method, apparatus and program for migrating between striped storage and parity striped storage |
| US7311928B2 (en) * | 2003-12-09 | 2007-12-25 | Briant Burke | Topical compositions containing tea tree oil for treatment of viral lesions |
| US7723063B2 (en) * | 2004-04-28 | 2010-05-25 | Intrinsic Lifesciences | Methods for measuring levels of bioactive human hepcidin |
| US20060110405A1 (en) * | 2004-08-20 | 2006-05-25 | Buckheit Robert W Jr | Plasma or serum fraction for treatment and prevention of viral infections and related conditions |
| NZ587255A (en) * | 2005-01-13 | 2012-03-30 | Novartis Vaccines & Diagnostic | Elisa assays using prion-specific peptide reagents |
| EP1855112A1 (en) * | 2006-05-10 | 2007-11-14 | Inserm | Method for the in vitro screening of compounds inhibiting production of infectious HIV-1 virions |
| US8200520B2 (en) | 2007-10-03 | 2012-06-12 | International Business Machines Corporation | Methods, systems, and apparatuses for automated confirmations of meetings |
| JP5662309B2 (ja) * | 2008-04-01 | 2015-01-28 | イネイト・イムノセラピューティクス・リミテッド | 腫瘍性疾患を治療するための組成物および方法 |
| CA2719252C (en) * | 2008-04-01 | 2016-01-19 | Innate Therapeutics Limited | Anti-infective agents comprising muramyl dipeptide microparticles and uses thereof |
| NZ571665A (en) * | 2008-09-30 | 2011-01-28 | Innate Therapeutics Ltd | Compositions and methods for treatment of radiation exposure utilising cross-linked muramyl dipeptide microparticles |
| JPWO2010134305A1 (ja) | 2009-05-18 | 2012-11-08 | 国立大学法人 東京医科歯科大学 | Ｈｉｖ立体構造認識抗体誘導ペプチド抗原、及びその合成方法 |
| NZ577731A (en) * | 2009-06-16 | 2010-08-27 | Innate Therapeutics Ltd | Compositions and methods for treatment of multiple sclerosis |
| CA2793959C (en) | 2010-03-25 | 2019-06-04 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
| RU2517084C2 (ru) * | 2010-08-06 | 2014-05-27 | Олег Ильич Эпштейн | Способ и средство для ингибирования продукции или усиления элиминации белка р24 |
| CN103502264A (zh) | 2011-04-04 | 2014-01-08 | 国立大学法人东京医科齿科大学 | Hiv立体结构识别抗体诱导肽 |
| PT2691530T (pt) | 2011-06-10 | 2018-05-10 | Univ Oregon Health & Science | Glicoproteínas e vectores recombinantes cmv |
| EP2568289A3 (en) | 2011-09-12 | 2013-04-03 | International AIDS Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies |
| EP2586461A1 (en) | 2011-10-27 | 2013-05-01 | Christopher L. Parks | Viral particles derived from an enveloped virus |
| ES2631608T3 (es) | 2012-06-27 | 2017-09-01 | International Aids Vaccine Initiative | Variante de la glicoproteína Env del VIH-1 |
| US20150065381A1 (en) | 2013-09-05 | 2015-03-05 | International Aids Vaccine Initiative | Methods of identifying novel hiv-1 immunogens |
| EP2873423B1 (en) | 2013-10-07 | 2017-05-31 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
| US10174292B2 (en) | 2015-03-20 | 2019-01-08 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
| US9931394B2 (en) | 2015-03-23 | 2018-04-03 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
| WO2017093985A1 (en) * | 2015-12-05 | 2017-06-08 | Centre Hospitalier Universitaire Vaudois | Hiv binding agents |
| CN108997482B (zh) * | 2018-08-09 | 2025-09-09 | 东莞市朋志生物科技有限公司 | 用于检测hiv-1的合成肽 |
| EP3996815A2 (en) * | 2019-07-15 | 2022-05-18 | Lausanne University Hospital | Hiv binding agents |
| AU2022208435A1 (en) | 2021-01-18 | 2023-08-10 | Conserv Bioscience Limited | Coronavirus immunogenic compositions, methods and uses thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5528933A (en) * | 1978-08-21 | 1980-02-29 | Dai Ichi Seiyaku Co Ltd | Muramyldipeptide dimer |
| CA1341482C (en) * | 1984-10-31 | 2005-05-10 | Paul A. Luciw | Process for preparing fragments of aids-associated retroviruses |
| US4946945A (en) * | 1987-06-23 | 1990-08-07 | Allergy Immuno Technologies, Inc. | Immunotherapy agents for treatment of IgE mediated allergies |
| US5128319A (en) * | 1987-08-28 | 1992-07-07 | Board Of Regents, The University Of Texas System | Prophylaxis and therapy of acquired immunodeficiency syndrome |
| CA2025634A1 (en) * | 1989-09-19 | 1991-03-20 | Thomas Fuerst | Peptides including ctl epitopes of hiv proteins and use thereof |
| US6565842B1 (en) | 1995-06-07 | 2003-05-20 | American Bioscience, Inc. | Crosslinkable polypeptide compositions |
| CA2268372C (en) * | 1996-10-10 | 2012-11-27 | Probe International | Compositions and methods for treating viral infections |
-
1997
- 1997-10-10 CA CA2268372A patent/CA2268372C/en not_active Expired - Lifetime
- 1997-10-10 US US08/948,782 patent/US6043347A/en not_active Expired - Lifetime
- 1997-10-10 KR KR1020057016920A patent/KR100667121B1/ko not_active Expired - Lifetime
- 1997-10-10 CN CNB971987432A patent/CN1327896C/zh not_active Expired - Lifetime
- 1997-10-10 EP EP97910856A patent/EP0939835A4/en not_active Withdrawn
- 1997-10-10 AU AU48131/97A patent/AU732809B2/en not_active Expired
- 1997-10-10 BR BR9712289-0A patent/BR9712289A/pt not_active Application Discontinuation
- 1997-10-10 KR KR1019997003052A patent/KR100547049B1/ko not_active Expired - Lifetime
- 1997-10-10 WO PCT/US1997/018257 patent/WO1998015658A1/en not_active Ceased
- 1997-10-10 NZ NZ334941A patent/NZ334941A/xx not_active IP Right Cessation
- 1997-10-10 MX MXPA02010374A patent/MXPA02010374A/es active IP Right Grant
- 1997-10-10 JP JP10517749A patent/JP2001502315A/ja not_active Ceased
-
2000
- 2000-01-14 US US09/482,612 patent/US6258599B1/en not_active Expired - Lifetime
- 2000-10-02 US US09/677,554 patent/US6335017B1/en not_active Expired - Lifetime
-
2001
- 2001-11-05 US US09/985,581 patent/US6670181B2/en not_active Expired - Lifetime
-
2003
- 2003-10-28 US US10/695,112 patent/US20040141996A1/en not_active Abandoned
-
2006
- 2006-11-28 US US11/605,017 patent/US8110203B2/en not_active Expired - Fee Related
-
2008
- 2008-10-06 JP JP2008259812A patent/JP2009080118A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP0939835A1 (en) | 1999-09-08 |
| CA2268372C (en) | 2012-11-27 |
| KR20060041157A (ko) | 2006-05-11 |
| JP2009080118A (ja) | 2009-04-16 |
| HK1023371A1 (en) | 2000-09-08 |
| US20020086034A1 (en) | 2002-07-04 |
| KR100667121B1 (ko) | 2007-01-12 |
| US6335017B1 (en) | 2002-01-01 |
| AU732809B2 (en) | 2001-05-03 |
| JP2001502315A (ja) | 2001-02-20 |
| AU4813197A (en) | 1998-05-05 |
| MXPA02010374A (es) | 2003-04-25 |
| CN1327896C (zh) | 2007-07-25 |
| BR9712289A (pt) | 1999-08-31 |
| CN1234078A (zh) | 1999-11-03 |
| KR100547049B1 (ko) | 2006-02-01 |
| US6670181B2 (en) | 2003-12-30 |
| US6043347A (en) | 2000-03-28 |
| CA2268372A1 (en) | 1998-04-16 |
| EP0939835A4 (en) | 2004-10-27 |
| WO1998015658A1 (en) | 1998-04-16 |
| US20070154917A1 (en) | 2007-07-05 |
| US6258599B1 (en) | 2001-07-10 |
| KR20000048994A (ko) | 2000-07-25 |
| US20040141996A1 (en) | 2004-07-22 |
| US8110203B2 (en) | 2012-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ334941A (en) | Methods for treating infections using proteins which induce an immune response in one animal species but not in another | |
| Bishop et al. | Humoral immunity in experimental syphilis: I. The demonstration of resistance conferred by passive immunization | |
| Osterhaus et al. | Induction of protective immune response in cats by vaccination with feline leukemia virus iscom. | |
| Chang et al. | Stress-induced suppression of interferon production in virus-infected mice | |
| Hirsch et al. | Effects of anti-thymocyte serum on Rauscher virus infection of mice | |
| Zhang et al. | Longevity of Sm-p80-specific antibody responses following vaccination with Sm-p80 vaccine in mice and baboons and transplacental transfer of Sm-p80-specific antibodies in a baboon | |
| EP4226938A3 (en) | Coronavirus vaccine | |
| Ganz et al. | Responses of patients with neoplastic diseases to influenza virus vaccine | |
| Le Grand et al. | AIDS vaccine developments | |
| Giordanengo et al. | Cruzipain induces autoimmune response against skeletal muscle and tissue damage in mice | |
| Lang et al. | Suppressant effect of human or equine rabies immunoglobulins on the immunogenicity of post-exposure rabies vaccination under the 2-1-1 regimen: a field trial in Indonesia. MAS054 Clinical Investigator Group | |
| Ohishi et al. | Augmentation of Bovine Leukemia Virus (BLV)‐Specific Lymphocyte Proliferation Responses in Ruminants by Inoculation with BLV env‐Recombinant Vaccinia Virus: Their Role in the Suppression of BLV Replication | |
| Kempe et al. | Smallpox immunization in the United States | |
| Bretscher et al. | Vaccination against and treatment of tuberculosis, the leishmaniases and AIDS: perspectives from basic immunology and immunity to chronic intracellular infections | |
| Shelke et al. | Equine rabies immunoglobulin: A review | |
| Clements et al. | HIV infection and routine childhood immunization: a review | |
| Dezfulian et al. | Role of the mammary tumor virus in the immunogenicity of spontaneous mammary carcinomas of BALB/c mice and in the responsiveness of the hosts | |
| Finerty et al. | Mucosal immunization with experimental feline immunodeficiency virus (FIV) vaccines induces both antibody and T cell responses but does not protect against rectal FIV challenge | |
| NO890565L (no) | Forhindring og behandling av retroviral sykdom. | |
| Peckinpaugh et al. | Mass enteric live adenovirus vaccination during epidemic ARD | |
| CHOW | Gonadotropins of the swine pituitary III. Immunological specificity of swine metakentrin | |
| Hunsmann et al. | Active immunization with feline leukemia virus envelope glycoprotein suppresses growth of virus-induced feline sarcoma | |
| Decroix et al. | Mucosal Immunity Induced by Intramuscular Administration of Free Peptides In‐Line with PADRE: IgA Antibodies to the ELDKWA Epitope of HIV gp41 | |
| Haagensen Jr et al. | Immunologic control of the ascites form of murine adenocarcinoma 755. I. Protection with syngeneic immune serum or lymphoid cells | |
| Hall et al. | Boosterable IgE antibody response in mice without the use of adjuvant |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) | ||
| ASS | Change of ownership |
Owner name: INNATE IMMUNOTHERAPEUTICS LIMITED, NZ Effective date: 20150522 |
|
| EXPY | Patent expired |